Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442 9. S9.4.2-4. Robinson TG, Potter JF, Ford GA, et al. Effects of antihyperten- sive treatment after acute stroke in the Continue or Stop Post-Stroke AntihypertensivesCollaborativeStudy(COSSACS):aprospective,ran- domised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767 75. S9.4.2-5. He J, ZhangY, Xu T, et al. Effects of immediate blood pressure reduc- tion on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479 89. S9.4.2-6. Wang H, Tang Y, Rong X, et al. Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis. PLoS ONE. 2014;9:e97917. S9.4.2-7. Zhao R, Liu F-D, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long- term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore). 2015;94:e896. S9.4.2-8. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev. 2014;10:CD000039. S9.4.2-9. Sandset EC, Bath PMW, Boysen G, et al. The angiotensin-recep- tor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741 50. S9.4.2-10. Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563 704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med. 2007;25:32 8. S9.4.2-11. Leonardi-Bee J, Bath PM, Phillips SJ, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315 20. S9.4.2-12. Castillo J, Leira R, Garcia MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35:520 6. S9.4.2-13. Vemmos KN, Tsivgoulis G, Spengos K, et al. U-shaped relation- ship between mortality and admission blood pressure in patients with acute stroke. J Intern Med. 2004;255:257 65. S9.4.2-14. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2013;44:870 947. 9.4.3. Secondary Stroke Prevention S9.4.3-1. Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032 40. S9.4.3-2. Lakhan SE, Sapko MT. Blood pressure lowering treatment for pre- venting stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2009;2:30. S9.4.3-3. PROGRESS Collaborative Group. Randomised trial of a perin- dopril-based blood-pressure-lowering regimen among 6 105 indi- viduals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033 41. S9.4.3-4. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710 7. S9.4.3-5. Lee M, Saver JL, Hong K-S, et al. Renin-angiotensin system modu- lators modestly reduce vascular risk in persons with prior stroke. Stroke. 2012;43:113 9. S9.4.3-6. Wang W-T, You L-K, Chiang C-E, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suf- fered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore). 2016;95:e3302. S9.4.3-7. Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduc- tion and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2017;69:171 9. S9.4.3-8. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. SPS3 Study Group. Lancet. 2013;382:507 15. S9.4.3-9. Arima H, Chalmers J, Woodward M, et al. Lower target blood pres- sures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201 8. S9.4.3-10. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S9.4.3-11. Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66:641 6. S9.4.3-12. Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke. 2004;35:731 5. S9.4.3-13. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004;62:569 73. S9.4.3-14. Toschke AM, Gulliford MC, Wolfe CDA, et al. Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database. J Hypertens. 2011;29:154 60. S9.4.3-15. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the preven- tion of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American StrokeAssociation. Stroke. 2014;45:2160 236. S9.4.3-16. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of car- diovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162 72. 9.5. Peripheral Artery Disease S9.5-1. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17 24. S9.5-2. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e99 events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913 22. S9.5-3. BavryAA,Anderson RD, GongY, et al. Outcomes among hyperten- sive patients with concomitant peripheral and coronary artery dis- ease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48 53. S9.5-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163 8. S9.5-5. Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long- term follow-up of participants with peripheral arterial disease dur- ing ALLHAT. J Gen Intern. Med. 2014;29:1475 83. 9.6. Diabetes Mellitus S9.6-1. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603 15. S9.6-2. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CD008277. S9.6-3. Cushman WC, Evans GW, Byington RP, et al. Effects of inten- sive blood-pressure control in type 2 diabetes mellitus. ACCORD Study. N Engl J Med. 2010;362:1575 85. S9.6-4. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S9.6-5. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721 8. S9.6-6. Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015;66:1123 9. S9.6-7. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S9.6-8. Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabe- tes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401 8. S9.6-9. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospec- tively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410 9. S9.6-10. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fast- ing glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401 9. S9.6-11. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047 56. S9.6-12. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208 19. S9.6-13. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of theAmerican College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S9.6-14. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J. 1991;121:1268 73. S9.6-15. Tarnow L, Rossing P, Gall MA, et al. Prevalence of arterial hyper- tension in diabetic patients before and after the JNC-V. Diabetes Care. 1994;17:1247 51. S9.6-16. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412 9. S9.6-17. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434 44. S9.6-18. Do DV, Wang X, Vedula SS, et al. Blood pressure control for dia- betic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127. S9.6-19. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure con- trol on diabetic microvascular complications in patients with hyperten- sion and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54 64. S9.6-20. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645 52. S9.6-21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703 13. S9.6-22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyperten- sion: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755 62. S9.6-23. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens. 2011;29:1253 69. S9.6-24. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S9.6-25. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. S9.6-26. PerkovicV, RodgersA. Redefining blood-pressure targets SPRINT starts the marathon. N Engl J Med. 2015;373:2175 8. S9.6-27. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727 36. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832 42. 9.7. Metabolic Syndrome S9.7-1. Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014;15:329 41. S9.7-2. Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evi- dence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17:558. S9.7-3. Ruderman NB, Shulman GI. Metabolic syndrome. Jameson JL. Endocrinology: Adult & Pediatric. 2015; Elsevier Saunders: Philadelphia, PA:752 9. S9.7-4. Mozumdar A, Liguori G. Persistent increase of prevalence of meta- bolic syndrome among U.S. adults: NHANES III to NHANES 1999 2006. Diabetes Care. 2011;34:216 9. S9.7-5. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167 74. S9.7-6. Chen J, Gu D, Chen C-S, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100 6. S9.7-7. Barzilay JI, Davis BR, Whelton PK. The glycemic effects of anti- hypertensive medications. Curr Hypertens Rep. 2014;16:410. S9.7-8. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29 35. S9.7-9. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syn- drome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008;168:207 17. S9.7-10. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832 42. S9.7-11. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical out- comes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31:353 60. S9.7-12. Laurent S, Boutouyrie P; Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014;64:709 16. S9.7-13. Reisin E, Owen J. Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection. J Am Soc Hypertens. 2015;9:156 59; quiz 160. 9.8. Atrial Fibrillation S9.8-1. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832 9. S9.8-2. Zhao D, Wang Z-M, Wang L-S. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29:475 85. S9.8-3. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109 16. S9.8-4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199 267. S9.8-5. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0 1: a nation- wide cohort study. Thromb Haemost. 2012;107:1172 9. S9.8-6. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a caus- ative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91:9G 14G. S9.8-7. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751 6. S9.8-8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022 31. S9.8-9. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712 9. S9.8-10. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54:2023 31. S9.8-11. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611 6. 9.9. Valvular Heart Disease S9.9-1. Rieck E, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovas- cular events. Hypertension. 2012;60:90 7. S9.9-2. Eleid MF, Nishimura RA, Sorajja P, et al. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation. 2013;128:1349 53. S9.9-3. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015;16:834 41. S9.9-4. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptom- atic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J. 2004;147:E19. S9.9-5. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994;331:689 94. S9.9-6. Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med. 2005;353:1342 9. 9.10. Aortic Disease S9.10 1. Genoni M, Paul M, Jenni R, et al. Chronic beta-blocker ther- apy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg. 2001;19: 606 10. S9.10 2. Suzuki T, Isselbacher EM, Nienaber CA, et al. Type-selective ben- efits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2012;109:122 7. S9.10 3. Masuda Y, Yamada Z, Morooka N, et al. Prognosis of patients with medically treated aortic dissections. Circulation. 1991;84: III7 13. S9.10 4. Rampoldi V, Trimarchi S, Eagle KA, et al. Simple risk models to predict surgical mortality in acute type A aortic dissection: the International Registry of Acute Aortic Dissection score. Ann Thorac Surg. 2007;83:55 61. S9.10 5. Suzuki T, Mehta RH, Ince H, et al. Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD). Circulation. 2003;108(suppl 1):II312 I317. S9.10 6. Mehta RH, O'Gara PT, Bossone E, et al. Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. J Am Coll Cardiol. 2002;40: 685 92. S9.10 7. Chan KK, Lai P, Wright JM. First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissection. Cochrane Database Syst Rev. 2014;2:CD010426. S9.10 8. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/ AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic dis- ease. a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American StrokeAssociation, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society forVascular Medicine. Circulation. 2010;121:e266 369. S9.10 9. Gaddum NR, Keehn L, Guilcher A, et al. Altered dependence of aortic pulse wave velocity on transmural pressure in hyperten- sion revealing structural change in the aortic wall. Hypertension. 2015;65:362 9. S9.10-10. Zhang L, Tian W, Feng R, et al. Prognostic impact of blood pres- sure variability on aortic dissection patients after endovascular therapy. Medicine (Baltimore). 2015;94:e1591. 10. Special Patient Groups 10.1. Race and Ethnicity S10.1-1. Yoon SSS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011 2014. NCHS Data Brief. 2015:1 8. S10.1-2. Margolis KL, Piller LB, Ford CE, et al. Blood pressure con- trol in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2007;50: 854 61. S10.1-3. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, et al. Blood pres- sure control and cardiovascular outcomes in high-risk Hispanic patients findings from the InternationalVerapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151:1072 9. S10.1-4. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S10.1-5. Centers for Disease Control and Prevention. Compressed Mortality File: Underlying Cause-of-Death 1999 2013. 2014. Available at: https://wonder.cdc.gov/mortsql.html. Accessed November 2, 2017. S10.1-6. Guzman NJ. Epidemiology and management of hypertension in the Hispanic population: a review of the available literature. Am J Cardiovasc Drugs. Am J Cardiovasc Drugs. 2012;12: 165 78. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e101 S10.1-7. Sorlie PD, Allison MA, Aviles-Santa ML, et al. Prevalence of hypertension, awareness, treatment, and control in the Hispanic Community Health Study/Study of Latinos. Am J Hypertens. 2014;27:793 800. S10.1-8. Rodriguez CJ, Allison M, Daviglus ML, et al. Status of cardio- vascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. Circulation. 2014;130:593 625. S10.1-9. Parsa A, Kao WHL, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369:2183 96. S10.1-10. Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropa- thy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83:114 20. S10.1-11. Langefeld CD, Divers J, Pajewski NM, et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015;87:169 75. S10.1-12. Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016;27:2842 50. 10.1.1. Racial and Ethnic Differences in Treatment S10.1.1-1. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374 84. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832 42. S10.1.1-3. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodip- ine, and lisinopril. JAMA. 2005;293:1595 608. S10.1.1-4. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical out- comes by race in hypertensive patients with and without the meta- bolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008;168:207 17. S10.1.1-5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981 97. S10.1.1-6. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S10.1.1-7. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pres- sure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421 31. S10.1.1-8. Odedosu T, Schoenthaler A, Vieira DL, et al. Overcoming barriers to hypertension control in African Americans. Cleve Clin J Med. 2012;79:46 56. S10.1.1-9. Ferdinand KC. Management of high blood pressure in African Americans and the 2010 ISHIB consensus statement: meet- ing an unmet need. J Clin Hypertens (Greenwich). 2010;12: 237 9. S10.1.1-10. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780 800. S10.1.1-11. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101:22S 32. S10.1.1-12. Saunders E, Weir MR, Kong BW, et al. A comparison of the effi- cacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707 13. S10.1.1-13. Cushman WC, Reda DJ, Perry HM, et al. Regional and racial dif- ferences in response to antihypertensive medication use in a ran- domized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 2000;160:825 31. S10.1.1-14. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141:614 27. S10.1.1-15. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163 8. S10.1.1-16. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417 28. S10.1.1-17. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141 4. S10.1.1-18. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4 16. S10.1.1-19. Fretheim A, Odgaard-Jensen J, Brors O, et al. Comparative effec- tiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 2012;10:33. S10.1.1-20. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kid- ney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta- analysis. Ann Intern Med. 2003;139:244 52. S10.1.1-21. Law MR, Morris JK, Wald NJ. Use of blood pressure lower- ing drugs in the prevention of cardiovascular disease: meta- analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: b1665. 10.2. Sex-Related Issues S10.2-1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S10.2-2. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihyperten- sive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997;126:761 7. S10.2-3. Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669 80. S10.2.1-1. Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669 80. S10.2.1-2. Wenger NK, Ferdinand KC, Bairey Merz CN, et al. Women, hypertension, and the Systolic Blood Pressure Intervention Trial. Am J Med. 2016;129:1030 6. S10.2.1-3. FletcherA, Beevers DG, Bulpitt C, et al. Beta adrenoceptor block- ade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:219 27. S10.2.1-4. Jansen J, Bonner C, McKinn S, et al. General practitioners' use of absolute risk versus individual risk factors in cardiovas- cular disease prevention: an experimental study. BMJ OPEN. 2014;4:e004812. S10.2.1-5. Lewis CE, Grandits A, Flack J, et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med. 1996;156:377 85. S10.2.1-6. Kloner RA, Sowers JR, DiBona GF, et al. Sex- and age-related anti- hypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77:713 22. S10.2.1-7. Igho Pemu P, Ofili E. Hypertension in women: part I. J Clin Hypertens (Greenwich). 2008;10:406 10. S10.2.2-1. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004;90:1499 504. S10.2.2-2. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in preg- nancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122 31. S10.2.2-3. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011. S10.2.2-4. Pucci M, Sarween N, Knox E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol. 2015;8:221 31. S10.2.2-5. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angio- tensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int. 2012;2012:658310. S10.2.2-6. Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol. 2000;96:849 60. S10.2.2-7. Garovic VD, August P. Preeclampsia and the future risk of hypertension: the pregnant evidence. Curr Hypertens Rep. 2013;15:114 21. S10.2.2-8. Kessous R, Shoham-Vardi I, Pariente G, et al. Long-term mater- nal atherosclerotic morbidity in women with pre-eclampsia. Heart. 2015;101:442 6. S10.2.2-9. Veerbeek JHW, Hermes W, Breimer AY, et al. Cardiovascular dis- ease risk factors after early-onset preeclampsia, late-onset pre- eclampsia, and pregnancy-induced hypertension. Hypertension. 2015;65:600 6. S10.2.2-10. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2:CD002252. S10.2.2-11. Nabhan AF, Elsedawy MM. Tight control of mild-moderate pre- existing or non-proteinuric gestational hypertension. Cochrane Database Syst Rev. 2011:CD006907. S10.2.2-12. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003:CD002863. S10.2.2-13. Magee LA, von Dadelszen P, Rey E, et al. Less-tight ver- sus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407 17. S10.2.2-14. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;7:CD001449. S10.2.2-15. Gulati M. Early identification of pregnant women at risk for preeclampsia: USPSTF recommendations on screening for pre- eclampsia. JAMA Cardiol. 2017;2:593 5. S10.2.2-16. Henderson JT, Thompson JH, Burda BU, et al. Preeclampsia screening: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317:1668 83. S10.2.2-17. Regitz-Zagrosek V, Blomstrom LC, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147 97. S10.2.2-18. Committee on Obstetric Practice. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension dur- ing pregnancy and the postpartum period. Obstet Gynecol. 2015;125:521 5. S10.2.2-19. Shimada C, Akaishi R, Cho K, et al. Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the sec- ond or third trimesters: a literature review. Hypertens Res. 2015;38:308 13. 10.3. Age-Related Issues 10.3.1. Older Persons S10.3.1-1. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years: a randomized clinical trial. JAMA. 2016;315:2673 82. S10.3.1-2. Ettinger WH Jr, Fried LP, Harris T, et al. Self-reported causes of physical disability in older people: the Cardiovascular Health Study. CHS Collaborative Research Group. J Am Geriatr Soc. 1994;42:1035 44. S10.3.1-3. Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA. 1997;277:728 34. S10.3.1-4. den Ouden MEM, Schuurmans MJ, Mueller-Schotte S, et al. Do subclinical vascular abnormalities precede impaired physical abil- ity and ADL disability? Exp Gerontol. 2014;58:1 7. S10.3.1-5. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347 60. S10.3.1-6. Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med. 2008;121:179 84.e3. S10.3.1-7. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130:1692 9. S10.3.1-8. Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9:197 205. S10.3.1-9. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255 64. S10.3.1-10. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757 64. S10.3.1-11. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hyperten- sion. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823 9. S10.3.1-12. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyper- tension in patients 80 years of age or older. N Engl J Med. 2008;358:1887 98. S10.3.1-13. Tinetti ME, Han L, Lee DSH, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174:588 95. S10.3.1-14. Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. S10.3.1-15. Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intel- lect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59:383 9. S10.3.1-16. Margolis KL, Palermo L, Vittinghoff E, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabe- tes: the ACCORD trial. J Gen Intern Med. 2014;29:1599 606. S10.3.1-17. Bavishi C, Bangalore S, Messerli FH. Outcomes of intensive blood pressure lowering in older hypertensive patients. J Am Coll Cardiol. 2017;69:486 93. S10.3.1-18. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hyper- tension. J Neurol. 2017;264:1567 82. 10.3.2. Children and Adolescents S10.3.2-1. Moser M, Roccella EJ. The treatment of hypertension: a remark- able success story. J Clin Hypertens (Greenwich). 2013;15:88 91. S10.3.2-2. Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children andAdolescents: Summary Report. 2012; National Heart, Lung, and Blood Institute, U.S. Department of Health and Human Services: Bethesda, MD:S1 S44; NIH Publication No. 12 7486. S10.3.2-3. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Integrated guidelines for cardiovascu- lar health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213 56. S10.3.2-4. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e103 S10.3.2-5. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63:1116 35. S10.3.2-6. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure moni- toring. J Hypertens. 2013;31:1731 68. S10.3.2-7. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904. 11. Other Considerations 11.1. Resistant Hypertension S11.1-1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diag- nosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403 19. S11.1-2. Persell SD. Prevalence of resistant hypertension in the United States, 2003 2008. Hypertension. 2011;57:1076 80. S11.1-3. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analy- sis of the prevalence of resistant hypertension in treated hyperten- sive populations. Am J Hypertens. 2015;28:355 61. S11.1-4. Smith SM, Huo T, Delia Johnson B, et al. Cardiovascular and mor- tality risk of apparent resistant hypertension in women with sus- pected myocardial ischemia: a report from the NHLBI-sponsored WISE Study. J Am Heart Assoc. 2014;3:e000660. S11.1-5. Tanner RM, Calhoun DA, Bell EK, et al. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014;63:781 8. S11.1-6. Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127:71 81.e1. S11.1-7. Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hyperten- sion: determination of prevalence, risk factors, and comorbidi- ties in a large, population-based cohort. Hypertension. 2014;63: 451 8. S11.1-8. Rosa J, Widimsky P, Waldauf P, et al. Role of adding spironolac- tone and renal denervation in true resistant hypertension: one- year outcomes of randomized PRAGUE-15 Study. Hypertension. 2016;67:397 403. S11.1-9. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393 401. S11.1-10. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activa- tion therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, pla- cebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58: 765 73. S11.1-11. Stergiou GS, Makris T, Papavasiliou M, et al. Comparison of anti- hypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23:883 9. S11.1-12. Liu G, Zheng XX, Xu YL, et al. Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta- analysis. J Hum Hypertens. 2015;29:159 66. S11.1-13. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the opti- mal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386: 2059 68. S11.1-14. Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol. 2009;62:158 66. S11.1-15. Dahal K, Kunwar S, Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analy- sis of randomized and nonrandomized studies. Am J Hypertens. 2015;28:1376 85. S11.1-16. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlo- dipine on renal outcomes in hypertensive nephrosclerosis: a ran- domized controlled trial. JAMA. 2001;285:2719 28. 11.2. Hypertensive Crises Emergencies and Urgencies S11.2-1. Farias S, Peacock WF, Gonzalez M, et al. Impact of initial blood pressure on antihypertensive response in patients with acute hyper- tension. Am J Emerg Med. 2014;32:833 6. S11.2-2. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure A Pilot Study (PRONTO). Am Heart J. 2014;167:529 36. S11.2-3. Papadopoulos DP, Sanidas EA, Viniou NA, et al. Cardiovascular hypertensive emergencies. Curr Hypertens Rep. 2015;17:5. S11.2-4. Manning L, Robinson TG, Anderson CS. Control of blood pressure in hypertensive neurological emergencies. Curr. Hypertens Rep. 2014;16:436. S11.2-5. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm. 2009;66:1343 52. S11.2-6. Rhoney D, Peacock WF. Intravenous therapy for hyperten- sive emergencies, part 2. Am J Health Syst Pharm. 2009;66: 1448 57. S11.2-7. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268:336 45. S11.2-8. Perez MI, Musini VM. Pharmacological interventions for hyperten- sive emergencies: a Cochrane systematic review. J Hum Hypertens. 2008;22:596 607. S11.2-9. Gifford RW Jr. Current practices in general medicine. 7. Treatment of hypertensive emergencies including use of sodium nitroprusside. Proc Staff Meet Mayo Clin. 1959;34:387 94. S11.2-10. Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care. 2011;15:R157. S11.2-11. Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ OPEN. 2013;3:e002338. S11.2-12. Varon J, Soto-Ruiz KM, Baumann BM, et al. The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? Postgrad Med. 2014;126:124 30. S11.2-13. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355 65. 11.3. Cognitive Decline and Dementia S11.3-1. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154 60. S11.3-2. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347 51. S11.3-3. Forette F, Seux M-L, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046 52. S11.3-4. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a random- ized double-blind intervention trial. J Hypertens. 2003;21:875 86. S11.3-5. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pres- sure lowering with perindopril and indapamide therapy on demen- tia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069 75. S11.3-6. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683 9. S11.3-7. Prince M, Wimo A, Guerchet M, et al. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. 2015; Alzheimer's Disease International: London, UK:10 27. S11.3-8. Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59:1764 7. S11.3-9. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487 99. S11.3-10. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:1683 9. S11.3-11. Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology. 2005;64:1548 52. S11.3-12. Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its con- trol. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke. 1996;27:2262 70. S11.3-13. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27:1274 82. S11.3-14. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46:200 4. S11.3-15. Skoog I. A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord. 1998;9(suppl 1):13 9. S11.3-16. Hughes TM, Sink KM. Hypertension and its role in cognitive function: current evidence and challenges for the future. Am J Hypertens. 2016;29:149 57. S11.3-17. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757 64. S11.3-18. Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pres- sure lowering on cardiovascular outcomes in normal weight, over- weight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension. 2010;55:1193 8. S11.3-19. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699 702. S11.3-20. Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174:324 33. S11.3-21. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system block- ade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10:43 53. S11.3-22. Diener H-C, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875 84. 11.4. Sexual Dysfunction and Hypertension S11.4-1. Nunes KP, Labazi H, Webb RC. New insights into hypertension- associated erectile dysfunction. Curr Opin Nephrol Hypertens. 2012;21:163 70. S11.4-2. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460 3. S11.4-3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50 6. S11.4-4. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dys- function and subsequent cardiovascular disease. JAMA. 2005;294:2996 3002. S11.4-5. Shin D, Pregenzer G Jr, Gardin JM. Erectile dysfunction: a disease marker for cardiovascular disease. Cardiol Rev. 2011;19:5 11. S11.4-6. Martin SA, Atlantis E, Lange K, et al. Predictors of sexual dys- function incidence and remission in men. J Sex Med. 2014;11: 1136 47. S11.4-7. Vasquez EC, Gava AL, Graceli JB, et al. Novel therapeutic tar- gets for phosphodiesterase 5 inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis. Curr Pharm Biotechnol. 2016;17:347 64. S11.4-8. Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in essential hypertension. Curr Hypertens Rep. 2008;10:52 7. S11.4-9. Al Khaja KAJ, Sequeira RP, Alkhaja AK, et al. Antihypertensive drugs and male sexual dysfunction: a review of adult hyperten- sion guideline recommendations. J Cardiovasc Pharmacol Ther. 2016;21:233 44. 11.5. Patients Undergoing Surgical Procedures S11.5-1. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349 61. S11.5-2. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J. 2001;141:148 53. S11.5-3. Wallace AW, Au S, Cason BA. Association of the pattern of use of perioperative -blockade and postoperative mortality. Anesthesiology. 2010;113:794 805. S11.5-4. Andersson C, Merie C, Jorgensen M, et al. Association of -blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncar- diac surgery: a Danish nationwide cohort study. JAMA Intern Med. 2014;174:336 44. S11.5-5. Hoeks SE, Scholte OpReimer WJM, van Urk H, et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg. 2007;33:13 9. S11.5-6. Barrett TW, Mori M, De Boer D. Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgery. J Hosp Med. 2007;2:241 52. S11.5-7. London MJ, Hur K, Schwartz GG, et al. Association of periopera- tive -blockade with mortality and cardiovascular morbidity fol- lowing major noncardiac surgery. JAMA. 2013;309:1704 13. S11.5-8. Turan A, You J, Shiba A, et al. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mor- tality after noncardiac surgery. Anesth Analg. 2012;114:552 60. S11.5-9. Rosenman DJ, McDonald FS, Ebbert JO, et al. Clinical conse- quences of withholding versus administering renin-angiotensin- aldosterone system antagonists in the preoperative period. J Hosp Med. 2008;3:319 25. S11.5-10. Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus con- tinuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017;126:16 27. S11.5-11. Fleisher LA. Preoperative evaluation of the patient with hyperten- sion. JAMA. 2002;287:2043 6. S11.5-12. Howell SJ, Sear JW, Foex P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth. 2004;92:570 83. S11.5-13. Hart GR, Anderson RJ. Withdrawal syndromes and the cessa- tion of antihypertensive therapy. Arch Intern Med. 1981;141: 1125 7. S11.5-14. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. POISE Study Group. Lancet. 2008;371:1839 47. S11.5-15. Charlson ME, MacKenzie CR, Gold JP, et al. The preoperative and intraoperative hemodynamic predictors of postoperative myocar- dial infarction or ischemia in patients undergoing noncardiac sur- gery. Ann Surg. 1989;210:637 48. S11.5-16. Cheung AT. Exploring an optimum intra/postoperative manage- ment strategy for acute hypertension in the cardiac surgery patient. J Card Surg. 2006;21(suppl 1):S8 14. S11.5-17. Dix P, Howell S. Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery. Br J Anaesth. 2001;86:789 93. S11.5-18. Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst Pharm. 2004;61: 1661 73. S11.5-19. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: com- parative studies of clevidipine to nitroglycerin, sodium nitroprus- side, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107:1110 21. S11.5-20. Espinosa A, Ripolles-Melchor J, Casans-Frances R, et al. Perioperative use of clevidipine: a systematic review and meta- analysis. PLoS ONE. 2016;11:e0150625. S11.5-21. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/ AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: execu- tive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:2215 45. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e105 S11.5-22. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458 73. S11.5-23. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413 46. S11.5-24. Wolfsthal SD. Is blood pressure control necessary before surgery? Med Clin North Am. 1993;77:349 63. S11.5-25. Goldman L, Caldera DL. Risks of general anesthesia and elec- tive operation in the hypertensive patient. Anesthesiology. 1979;50:285 92. S11.5-26. Towne JB, Bernhard VM. The relationship of postoperative hypertension to complications following carotid endarterectomy. Surgery. 1980;88:575 80. S11.5-27. Aronson S, Boisvert D, Lapp W. Isolated systolic hyper- tension is associated with adverse outcomes from coro- nary artery bypass grafting surgery. Anesth Analg. 2002;94: 1079 84. S11.5-28. Foex P, Meloche R, Prys-Roberts C. Studies of anaesthesia in rela- tion to hypertension. 3. Pulmonary gas exchange during spontane- ous ventilation. Br J Anaesth. 1971;43:644 61. S11.5-29. Gerber JG, Nies AS. Abrupt withdrawal of cardiovascular drugs. N Engl J Med. 1979;301:1234 5. S11.5-30. Rangno RE, Langlois S. Comparison of withdrawal phenom- ena after propranolol, metoprolol, and pindolol. Am Heart J. 1982;104:473 8. S11.5-31. Walker PR, Marshall AJ, Farr S, et al. Abrupt withdrawal of ateno- lol in patients with severe angina. Comparison with the effects of treatment. Br Heart J. 1985;53:276 82. 12. Strategies to Improve Hypertension Treatment and Control 12.1. Adherence Strategies for Treatment of Hypertension 12.1.1. Antihypertensive Medication Adherence Strategies S12.1.1-1. Claxton AJ, Cramer J, Pierce C. A systematic review of the asso- ciations between dose regimens and medication compliance. Clin Ther. 2001;23:1296 310. S12.1.1-2. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihyperten- sive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24:302 16. S12.1.1-3. Schroeder K, Fahey T, Ebrahim S. How can we improve adher- ence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722 32. S12.1.1-4. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose com- binations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713 9. S12.1.1-5. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effec- tiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399 407. S12.1.1-6. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equiva- lent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898 909. S12.1.1-7. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26:2065 76. S12.1.1-8. Franklin SS, Thijs L, Hansen TW, et al. Significance of white- coat hypertension in older persons with isolated systolic hyper- tension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59: 564 71. S12.1.1-9. Holland N, Segraves D, Nnadi VO, et al. Identifying barriers to hypertension care: implications for quality improvement initia- tives. Dis Manag. 2008;11:71 77. S12.1.1-10. Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297 306. S12.1.1-11. Gwadry-Sridhar FH, Manias E, Lal L, et al. Impact of interven- tions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health. 2013;16:863 71. S12.1.1-12. Petrilla AA, Benner JS, Battleman DS, et al. Evidence-based interventions to improve patient compliance with antihy- pertensive and lipid-lowering medications. Int J Clin Pract. 2005;59:1441 51. S12.1.1-13. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304 14. S12.1.1-14. Krousel-Wood MA, Muntner P, Islam T, et al. Barriers to and determinants of medication adherence in hypertension manage- ment: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93:753 69. S12.1.1-15. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011. S12.1.1-16. Viswanathan M, Golin CE, Jones CD, et al. Closing the quality gap: revisiting the state of the science (vol. 4: medication adher- ence interventions: comparative effectiveness). Evid RepTechnol Assess (Full Rep). 2012:1 685. S12.1.1-17. Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15:90 6. 12.1.2. Strategies to Promote Lifestyle Modification S12.1.2-1. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardio- vascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:406 41. S12.1.2-2. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2): S76 99. 12.1.3. Improving Quality of Care for Resource- Constrained Populations S12.1.3-1. Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132:873 98. S12.1.3-2. Institute of Medicine (U.S.) Committee on Public Health Priorities to Reduce and Control Hypertension. A Population-Based Policy and Systems Change Approach to Prevent and Control Hypertension. 2010; National Academies Press: Washington, DC. S12.1.3-3. Margolius D, Bodenheimer T, Bennett H, et al. Health coaching to improve hypertension treatment in a low-income, minority popu- lation. Ann Fam Med. 2012;10:199 205. S12.1.3-4. Polgreen LA, Han J, Carter BL, et al. Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. Hypertension. 2015;66:1145 51. S12.1.3-5. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of community health workers in the care of people with hyperten- sion. Am J Prev Med. 2007;32:435 47. 12.2. Structured, Team-Based Care Interventions for Hypertension Control S12.2-1. Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748 55. S12.2-2. Clark CE, Smith LFP, Taylor RS, et al. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995. S12.2-3. Proia KK, ThotaAB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86 99. S12.2-4. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pres- sure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000718. S12.2-5. Shaw RJ, McDuffie JR, Hendrix CC, et al. Effects of nurse-man- aged protocols in the outpatient management of adults with chronic conditions: a systematic review and meta-analysis. Ann Intern Med. 2014;161:113 21. S12.2-6. Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2014;7: 828 34. S12.2-7. Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pres- sure control. Circ Cardiovasc Qual Outcomes. 2015;8:235 43. S12.2-8. Himmelfarb CRD, Commodore-Mensah Y, Hill MN. Expanding the role of nurses to improve hypertension care and control glob- ally. Ann Glob Health. 2016;82:243 53. S12.2-9. The Guide to Community Preventive Services (The Community Guide). Cardiovascular Disease: Team-Based Care to Improve Blood Pressure Control. 2012. Available at: https://www.thecom- munityguide.org/findings/cardiovascular-disease-team-based-care- improve-blood-pressure-control. Accessed June 1, 2017. S12.2-10. Centers for Disease Control and Prevention. Task Force recom- mends team-based care for improving blood pressure control. Press Release. May 15, 2012. Available at: https://www.cdc.gov/media/ 2017. S12.2-11. Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The effectiveness of pharmacist interventions on cardiovascular risk: The Multicenter Randomized Controlled RxEACH Trial. J Am Coll Cardiol. 2016;67:2846 54. S12.2-12. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of community health workers in the care of people with hypertension. Am J Prev Med. 2007;32:435 47. S12.2-13. Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol. 2015;65: 2118 36. S12.2-14. Patient-Centered Primary Care Collaborative. The Patient- Centered Medical Home: Integrating Comprehensive Medication Management to Optimize Patient Outcomes: Resource Guide. 2010.Available at: https://www.pcpcc.org/sites/default/files/media/ medmanagement.pdf. Accessed June 15, 2017. S12.2-15. Dunn SP, Birtcher KK, Beavers CJ, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015;66:2129 39. 12.3. Health Information Technology Based Strategies to Promote Hypertension Control 12.3.1. EHR and Patient Registries S12.3.1-1. Rakotz MK, Ewigman BG, Sarav M, et al. A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients. Ann Fam Med. 2014;12:352 8. S12.3.1-2. Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;64:2196 203. S12.3.1-3. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699 705. 12.3.2. Telehealth Interventions to Improve Hypertension Control S12.3.2-1. Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455 67; discussion 467 8. S12.3.2-2. Verberk WJ, Kessels AGH, Thien T. Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis. Blood Press Monit. 2011;16:149 55. S12.3.2-3. Agarwal R, Bills JE, Hecht TJW, et al. Role of home blood pres- sure monitoring in overcoming therapeutic inertia and improv- ing hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29 38. S12.3.2-4. Liu S, Dunford SD, Leung YW, et al. Reducing blood pressure with Internet-based interventions: a meta-analysis. Can J Cardiol. 2013;29:613 21. S12.3.2-5. Burke LE, Ma J, Azar KMJ, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scien- tific statement from the American Heart Association. Circulation. 2015;132:1157 213. S12.3.2-6. Li JS, Barnett TA, Goodman E, et al. Approaches to the prevention and management of childhood obesity: the role of social networks and the use of social media and related electronic technolo- gies: a scientific statement from the American Heart Association. Circulation. 2013;127:260 7. S12.3.2-7. Omboni S, Ferrari R. The role of telemedicine in hypertension man- agement: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17:535. 12.4. Improving Quality of Care for Patients With Hypertension 12.4.1. Performance Measures S12.4.1-1. Svetkey LP, Pollak KI,Yancy WS Jr, et al. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. Hypertension. 2009;54:1226 33. S12.4.1-2. de Lusignan S, Gallagher H, Jones S, et al. Audit-based educa- tion lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int. 2013;84:609 20. S12.4.1-3. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699 705. S12.4.1-4. Performance Management and Measurement. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2011. Available at: https://www.hrsa.gov/sites/ measurement.pdf. Accessed October 30, 2017. S12.4.1-5. Bardach NS, Wang JJ, De Leon SF, et al. Effect of pay-for-per- formance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310:1051 9. S12.4.1-6. Navar-Boggan AM, Shah BR, Boggan JC, et al. Variability in per- formance measures for assessment of hypertension control. Am Heart J. 2013;165:823 7. 